Bio-Path Holdings Announces Pre-Clinical Results Signaling Increased Potential for BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients BP1001-A_Obesity_Second_Efficacy_Milestone
Bio-Path Holdings Provides Key Clinical Updates BP1001-A_Update_Solid_Tumor_Response_AML_DurabilityDownload
Bio-Path Holdings Provides Update from Phase 1/1b Clinical Trial of BP1002 for Treatment of Refractory/Relapsed Acute Myeloid Leukemia BP1002_RR_AML_4th_Dose_Cohort_and_Significant_Patient_Response
